Genetic Engineering of T Cells for Immunotherapy

Overview

Journal Nat Rev Genet

Specialty Genetics

Date 2021 Feb 19

PMID 33603158

Citations 55

Authors

Gavin I Ellis

Neil C Sheppard

James L Riley

Affiliations

Soon will be listed here.

Abstract

Genetically engineered T cell immunotherapies have provided remarkable clinical success to treat B cell acute lymphoblastic leukaemia by harnessing a patient's own T cells to kill cancer, and these approaches have the potential to provide therapeutic benefit for numerous other cancers, infectious diseases and autoimmunity. By introduction of either a transgenic T cell receptor or a chimeric antigen receptor, T cells can be programmed to target cancer cells. However, initial studies have made it clear that the field will need to implement more complex levels of genetic regulation of engineered T cells to ensure both safety and efficacy. Here, we review the principles by which our knowledge of genetics and genome engineering will drive the next generation of adoptive T cell therapies.

Citing Articles

Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes.

Li R, Grosskopf A, Joslyn L, Stefanich E, Shivva V AAPS J. 2025; 27(2):55.

PMID: 40032717 DOI: 10.1208/s12248-025-01017-w.

Role of Peripheral Blood Regulatory T Cells and IL-2 in the Collateral Circulation of Acute Ischemic Stroke.

Zhang S, Rao C, Wen M, Zhang X, Zha Z, Gu T Int J Gen Med. 2025; 18:1075-1088.

PMID: 40026811 PMC: 11871876. DOI: 10.2147/IJGM.S504218.

Organ-on-chip for advancing CAR therapy.

Ngashangva L, Martin S Clin Transl Immunology. 2025; 14(2):e70024.

PMID: 40018376 PMC: 11862890. DOI: 10.1002/cti2.70024.

Regulatory T Cells for Stroke Recovery: A Promising Immune Therapeutic Strategy.

Li N, Wang H, Hu C, Qie S, Liu Z CNS Neurosci Ther. 2025; 31(1):e70248.

PMID: 39878387 PMC: 11775944. DOI: 10.1111/cns.70248.

Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy.

Ouladan S, Orouji E J Clin Oncol. 2025; 43(8):994-1005.

PMID: 39805063 PMC: 11895826. DOI: 10.1200/JCO-24-02081.

References

Foster A, Mahendravada A, Shinners N, Chang W, Crisostomo J, Lu A . Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40. Mol Ther. 2017; 25(9):2176-2188. PMC: 5589084. DOI: 10.1016/j.ymthe.2017.06.014. View

Wang J, DeClercq J, Hayward S, Li P, Shivak D, Gregory P . Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res. 2015; 44(3):e30. PMC: 4756813. DOI: 10.1093/nar/gkv1121. View

Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503. PMC: 6511988. DOI: 10.1038/s41591-018-0201-9. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Minutolo N, Sharma P, Poussin M, Shaw L, Brown D, Hollander E . Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor. J Am Chem Soc. 2020; 142(14):6554-6568. PMC: 7306176. DOI: 10.1021/jacs.9b11622. View

Yeo N, Chavez A, Lance-Byrne A, Chan Y, Menn D, Milanova D . An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods. 2018; 15(8):611-616. PMC: 6129399. DOI: 10.1038/s41592-018-0048-5. View

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Beavis P, Henderson M, Giuffrida L, Mills J, Sek K, Cross R . Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017; 127(3):929-941. PMC: 5330718. DOI: 10.1172/JCI89455. View

10.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

11.

Sather B, Romano Ibarra G, Sommer K, Curinga G, Hale M, Khan I . Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med. 2015; 7(307):307ra156. PMC: 4790757. DOI: 10.1126/scitranslmed.aac5530. View

12.

Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C . PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer. 2019; 7(1):209. PMC: 6686487. DOI: 10.1186/s40425-019-0685-y. View

13.

Kochenderfer J, Dudley M, Carpenter R, Kassim S, Rose J, Telford W . Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013; 122(25):4129-39. PMC: 3862276. DOI: 10.1182/blood-2013-08-519413. View

14.

Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10):3814-3826. PMC: 5096828. DOI: 10.1172/JCI87366. View

15.

Chen J, Lopez-Moyado I, Seo H, Lio C, Hempleman L, Sekiya T . NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019; 567(7749):530-534. PMC: 6546093. DOI: 10.1038/s41586-019-0985-x. View

16.

Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K . A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. Cancer Immunol Res. 2016; 4(8):658-68. DOI: 10.1158/2326-6066.CIR-16-0043. View

17.

van Loenen M, de Boer R, Amir A, Hagedoorn R, Volbeda G, Willemze R . Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A. 2010; 107(24):10972-7. PMC: 2890759. DOI: 10.1073/pnas.1005802107. View

18.

Ahmadi M, King J, Xue S, Voisine C, Holler A, Wright G . CD3 limits the efficacy of TCR gene therapy in vivo. Blood. 2011; 118(13):3528-37. DOI: 10.1182/blood-2011-04-346338. View

19.

Zhou X, Bailey-Bucktrout S, Jeker L, Penaranda C, Martinez-Llordella M, Ashby M . Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009; 10(9):1000-7. PMC: 2729804. DOI: 10.1038/ni.1774. View

20.

Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View